SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as the community rallies around the revival of OG memes and internet culture. With a focus on community building and shared conviction, supporters are expressing excitement about $RAGE's potential as a cultural reset. The community emphasizes that they are working towards their goals and are not to be faded.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO is trending as investors discuss its dividend payouts and relationship to Bitcoin's price movements. Community members are weighing the ETF's income potential against concerns about NAV erosion and comparing it to other crypto investment options. The ETF's capacity to mirror Bitcoin's performance while distributing dividends remains a key point of interest.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential, particularly around decentralized internet infrastructure and AI applications like Caffeine. Some believe ICP is undervalued and poised for growth, while others express skepticism based on its price history and tokenomics. Bullish arguments center on ICP's technology, growing network usage, and potential for Bitcoin DeFi integration.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins ($PENGU) is experiencing significant volatility, sparking heated debates within the community. While some investors express concerns about recent price drops and label it a scam, others remain optimistic, citing strong product sales and potential future growth, viewing the dip as a buying opportunity. Discussions revolve around potential catalysts like an ETF and broader market trends impacting altcoins.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTERION ($ASTER) is experiencing significant volatility, with community chatter focusing on a recent price pump and potential for further movement. Discussions include speculation around market manipulation, possible connections to CZ (Changpeng Zhao), and comparisons to other decentralized exchanges. Some traders are taking short positions, while others are anticipating a continued uptrend, highlighting the divided sentiment surrounding the crypto asset.

iPower, Inc. engages in the online retail and supply of consumer home, garden, in-home farming, pet, and wellbeing products. It sells its brands such as Simple Deluxe, YSSOA, Zenhydro, Flourish, iPOWER, iFarm, FluffyDream, ScratchMe, and HealSmart through zenhydro.com, simpledeluxe.com, and various third-party online platforms. The company offers grow light systems, advanced heating, ventilation and air conditioning (HVAC) systems, water pumps, heaters, chillers and filters, nutrient and fertilizer delivery systems, and various growing media typically made from soil, rock wool or coconut fiber. It also provides home goods supplies including commercial fans, floor and wall fans, storage and shelving units, and chairs. The company was founded by Chenlong Tan and Allan Huang on April 11, 2018 and is headquartered in Rancho Cucamonga, CA.

iPower Inc

iPower Inc. ($IPW) is trending due to a mix of factors, including discussions around its low float after a reverse split, potential for a squeeze, and strategic shifts into crypto. Community members are actively debating the stock's potential for significant gains, citing its small public float and comparing it to other companies in terms of valuation and growth prospects. Recent partnerships and news, along with mentions as a top gainer, contribute to the heightened interest and speculative buzz.

BlackRock Institutional Trust Company N.A. - iShares MSCI India ETF

iShares MSCI India ETF

The iShares MSCI India ETF ($INDA) is trending amid discussions of potential trade deals with the U.S. and a shift in global economic influence. Community members are weighing in on India's economic strengths, domestic-driven growth, and comparisons to China as an investment opportunity, while also considering factors like valuations, tariffs, and global economic conditions.

zkSync

ZK Crypto is trending as community members discuss its potential and recent developments within the ZKsync ecosystem, including EVM equivalence and enterprise blockchain solutions. Discussions also highlight mentions from key figures like Vitalik, sparking interest and speculation about its future value. The community is watching for price movement and further adoption.

Tri Pointe Homes, Inc. designs, constructs, and sells single-family homes and condominiums. It operates through the Homebuilding and Financial Services segments. The Homebuilding segment consists of six reportable segments: Maracay Homes, consisting of operations in Arizona, Pardee Homes, consisting of operations in California and Nevada, Quadrant Homes, consisting of operations in Washington, Trendmaker Homes, consisting of operations in Texas, TRI Pointe Homes, consisting of operations in California and Colorado, and Winchester Homes, consisting of operations in Maryland and Virginia. The Financial Services segment consists of its TRI Pointe Connect mortgage financing operations and its TRI Pointe Assurance title services operations. The company was founded in April 2009 and is headquartered in Incline Village, NV.

Tri Pointe Homes Inc.

Tri Pointe Homes ($TPH) is trending amid discussions around consumer sentiment and housing market dynamics, particularly following analyst ratings updates. The community is analyzing the company's financial health, free cash flow, and potential value compared to its peers, with some highlighting attractive metrics and strategic market entries. Discussions also touch on broader housing sector challenges like affordability and regional demand shifts.

Shoals Technologies Group, Inc. engages in the provision of electrical balance of system solutions for solar energy projects. Its EBOS components include cable assemblies, inline fuses, combiners, disconnects, recombiners, wireless monitoring systems, junction boxes, transition enclosures and splice boxes. The company was founded by Dean Solon in November 1996 and is headquartered in Portland, TN.

Shoals Technologies Group Inc - Ordinary Shares - Class A

SHLS is trending due to upcoming earnings and recent analyst activity, including upgrades and price target adjustments. Bullish sentiment is driven by the company's growth in the renewable energy sector and strategic initiatives in energy storage and data centers. The community is closely watching the earnings report, expecting it to reinforce the stock's upward trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?

Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates

Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Johnson &amp; Johnson’s (J&amp;J) stock&nbsp;fell 0.4% in premarket trade on Tuesday as investors positioned ahead of the healthcare giant’s quarterly results due Tuesday, with focus on its medical devices business, drug pipeline, and tariff exposure.The company is expected to post revenue of $23.76 billion, nearly flat from last year's $23.74 billion, according to estimates from Koyfin. Adjusted EPS is expected to be $2.76, down from $2.77 a year ago. EBITDA is expected to come in 0.6% lower at $8.58 billion, while EBIT is expected to tick up 0.5% to $8 billion.J&amp;J shares trade near $190.90, close to their 12-month average price target of $187.49, implying limited near-term upside. Analysts maintain a broadly positive stance, with 10 rating it a ‘Buy,’ 11 a ‘Hold,’ and two a ‘Strong Buy.’In July, J&amp;J cut its tariff-related cost forecast for the year to $200 million, down from $400 million, citing lower-than-expected impact on its medical devices business after the Trump administration paused some China and EU duties. CFO Joe Wolk said the company absorbed the costs while still raising its profit outlook, describing the tariff effect as “minimal.”Growth in the medtech unit is expected to be a bright spot, driven by sales from cardiovascular products such as Varipulse and Trupulse, and Abiomed’s Impella heart pumps. J&amp;J said in July that robotic surgery and cardiovascular devices will be the key engines of growth for its medtech unit.Attention will also be on Carvykti, J&amp;J’s blood cancer therapy developed with Legend Biotech, which recently received a U.S. FDA label update adding a black box warning for a rare intestinal inflammation. Regulators said the therapy’s benefits still outweigh risks, highlighting longer patient survival versus standard treatments.In immunology, the company faces renewed pressure from biosimilar competition to its top-selling drug Stelara. To offset potential declines, J&amp;J has been pursuing acquisitions, including reported talks to acquire Protagonist Therapeutics, its partner on an oral therapy for plaque psoriasis and ulcerative colitis. A deal would add late-stage drug Rusfertide, seen as complementary to J&amp;J’s immunology and oncology portfolios.Legal overhangs persist after a $966 million jury verdict in California earlier this month tied to talc-related cancer claims, which J&amp;J plans to appeal. The company maintains&nbsp;that its products are safe and asbestos-free.On Stocktwits, retail sentiment for J&amp;J was ‘extremely bullish’ amid a&nbsp; 2,200% surge in 24-hour message volume.One user predicted that J&amp;J shares could climb to the $196–$200 range after earnings, while others speculated the biotech might announce an Altimmune acquisition during Tuesday’s earnings call.<stembedurl>https://stocktwits.com/Wenwenwenwenwenwen/message/632192878</stembedurl><stembedurl>https://stocktwits.com/Ad7777/message/632156784</stembedurl><stembedurl>https://stocktwits.com/namv/message/632137184</stembedurl><a href="https://stocktwits.com/symbol/JNJ">J&amp;J’s stock</a> has risen 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

JNJ beat third-quarter earnings estimates but lowered guidance for the year 

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Equity

BMO Capital raised its price target on Protagonist Therapeutics to $112 from $72 and maintained an 'Outperform' rating, citing reports that Johnson &amp; Johnson may acquire the biotech firm.&nbsp;In a note to investors, the firm said its updated model better reflects the potential value of Protagonist’s two key drug assets, Rusfertide and Icotrokinra, for an acquirer, and that the market is “underpricing what Protagonist could be worth.”<a href="https://stocktwits.com/symbol/PTGX">Protagonist Therapeutics’ stock</a> fell 9% to $79.17 on Monday, marking its worst trading session in more than three months, before edging up 0.1% in after-hours trade.J&amp;J is reportedly in talks to buy Protagonist in a deal that would strengthen its existing partnership on an oral therapy for immune diseases such as plaque psoriasis and ulcerative colitis, for which J&amp;J already holds exclusive commercialization rights. The healthcare giant also owns nearly 4% of Protagonist’s shares, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/johnson-johnson-in-talks-to-buy-protagonist-therapeutics-38e0b69d">reported</a> last week.An acquisition would give J&amp;J access to Rusfertide, which has shown promise in late-stage trials for polycythemia vera, a rare blood cancer. Both Rusfertide and Icotrokinra would complement J&amp;J’s existing portfolio of immune and oncology treatments.Meanwhile, J&amp;J is seeking acquisitions to offset declining sales of its blockbuster immune-disease drug Stelara, now facing biosimilar competition.On Stocktwits, retail sentiment was ‘bullish’ for Protagonist Therapeutics with ‘extremely high’ message volume, while sentiment toward Johnson &amp; Johnson was ‘extremely bullish’ amid normal activity.One user called the pullback in Protagonist a “great buying opportunity,” arguing that retail investors were mistaken to think the company would sell for less than $5 billion.&nbsp;<stembedurl>https://stocktwits.com/outlawinvestor1/message/632143522</stembedurl>On the other hand, another user predicted the potential deal could value Protagonist shares&nbsp;at around $35.<stembedurl>https://stocktwits.com/Fugazi_/message/632134508</stembedurl>So far this year, Protagonist shares have more than doubled in value, while&nbsp;<a href="https://stocktwits.com/symbol/JNJ">Johnson &amp; Johnson shares</a> have gained about 35%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

So far this year, Protagonist shares (PTGX) have more than doubled in value, while Johnson & Johnson shares (JNJ) have gained about 35%. (Photo credit: Getty Images)

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In

The research firm said its higher target better reflects the value of Protagonist’s key drug assets, Rusfertide and Icotrokinra.

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal

PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.

RTW Investments' Rod Wong: Expect more deals in biotech space

Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the...

JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra

J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

PTGX
Protagonist Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PTGX News

PTGXProtagonist Therapeutics Inc